Cabozantinib (Cabometyx)
. Draft fact sheet, awaiting Henry's approval. Items marked [check] must be verified before publishing.
← All drugs · Search the portal
Facts
| Topic | Fact | Source (access date) |
|---|---|---|
| First approval | US: Cometriq capsules 29 Nov 2012; Cabometyx tablets 25 Apr 2016 (Exelixis). EU: Cometriq 21 Mar 2014, Cabometyx 9 Sep 2016 (Ipsen). China: not approved per secondary sources | Drugs@FDA via openFDA, https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA203756 (accessed 4 Nov 2026); Drugs@FDA via openFDA, https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA208692 (accessed 4 Nov 2026); EMA medicines report, https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx (accessed 4 Nov 2026); https://www.indianmed.cn/drug-news/t2nz0hzctd4y.html and https://www.sohu.com/a/1076774583_122732456 (4 Nov 2026; secondary, NMPA register not opened) |
| Mechanism | Tablet blocking MET, VEGFR2, RET and other kinases | http://static.cninfo.com.cn/finalpage/2020-11-03/1208675554.PDF (4 Nov 2026) |
| Use in osteosarcoma | Relapse (NCCN listed; Chinese guideline); first line in trials AOST2032 (with MAP, up to 40; suspended Oct 2026) and FOSTER (Europe, from age 4) | NCCN via secondary source https://www.cancertherapyadvisor.com/ddi/bone-cancer-treatment-pharmacologic-management/ (accessed 31 Oct 2026; primary NCCN not opened); Level 2 facts table; entries.json (portal export), sources opened 31 Oct to 3 Nov 2026 |
| Combined with | MAP (AOST2032); atezolizumab (TACOS, NCT05019703) | entries.json (portal export), sources opened 31 Oct to 3 Nov 2026 |
| Results | CABONE (aged 12+): osteosarcoma 5/42 (12%) responses, 14/42 (33%) without progression at 6 months | doi:10.1016/S1470-2045(19)30825-3 (3 Nov 2026) |
| Side effects | US label, most common (20% or more) alone: diarrhoea, tiredness, hand-foot skin reaction, decreased appetite, high blood pressure, nausea, vomiting, weight loss, constipation. Warnings include bleeding, perforation, jaw osteonecrosis | openFDA label API, https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22CABOMETYX%22 (accessed 4 Nov 2026) (Exelixis label, set id 3850cce2-6137-42e5-a792-d318c4a4b3b5) |
| Owner | Exelixis (originator, US); Ipsen (outside US and Japan); Takeda (Japan, approved there 2020). In patent | Drugs@FDA via openFDA, https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA208692 (accessed 4 Nov 2026); EMA medicines report (accessed 4 Nov 2026); Exelixis, https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-partner-takeda-receives-approval-japan (accessed 4 Nov 2026) |
| Regulatory | US, EU, UK: kidney, liver, thyroid cancers. China: no NMPA approval found; Chinese drug-information sites state it is not approved as of 2026 (secondary). Not osteosarcoma anywhere | entries.json; https://www.yaodey.com/drug/state_60.html and https://www.linchuangsy.com/Newsqa/Show/14269.html (accessed 4 Nov 2026) (secondary; NMPA register returned HTTP 412) |
Hypotheses and open points (not established fact)
- Adding cabozantinib to first-line MAP improves cure rates: being tested (AOST2032, FOSTER); unknown.